Document Page: First | Prev | Next | All | Image | This Release | Search
File: 970107_sep96_decls33_0002.txt
Subject: PREVENTION OF HEPATITIS A IN SOLDIERS
Unit: OTSG
Parent Organization: HSC
Box ID: BX003205
Folder Title: HEPATITIS A - VACCINES
Document Number: 1
Folder Seq #: 62
Enclosure 1.
Prevention of Hepatitis A in soldiers
I. Background
Hepatitis A can interrupt battle and force loss of territory.
It must be prevented. The Armed Forces Medical Intelligence
Center (AFMIC) indicates that hepatitis A is a "High risk" to
operations in Saudi Arabia based on the following observations.
A. 90% of Saudi children have antibody to hepatitis A by age
10. Virtually 100% of adults have antibody. (This figure
presumably also applies to potential adversaries.)
B. Hepatitis A is listed as the viral etiology for over 50%
of the reported acute hepatitis cases at local clinics.
C. In studies carried out by the Walter Reed Army Institute
of Research on soldiers of the 101st Airborne Division (Air
Assault), at Ft. Campbell, KY, we found that only 15% of
soldiers have antibody to hepatitis A.
II. Prevention of Hepatitis A by immune serum globulin
Since WWII, we have successfully used immune serum globulin
to prevent this disease. This is an unsatisfactory prophylaxis,
since uncomfortable shots of a plasma derived product must be
given every 6 months. Moreover, the requirements of Operation
Desert Shield have exhausted the available supply of ISG in the
United States. Permanent active immunization by means of a
vaccine is medically and logistically preferable.
III. Development of Hepatitis A vaccine
Realizing the need for a hepatitis A vaccine, WRAIR has
pioneered an effort to develop such a product. The first
formalin inactivated cell culture derived hepatitis A vaccine was
developed at the Walter Reed Army Institute of Research about 10
, and
all developed antibody. Further studies at Ft. Lewis,
Washington, confirmed the imnunogenicity and safety of this
prototype vaccine. Having demonstrated the feasibility of the
product, a Request For Proposals was published. We interviewed
several prospective industrial partners. "No-dollar agreements"
were signed with Smith Kline Beecham and the Swiss Serum
Institute. we provided them with extensive information on the
production of hepatitis A vaccine and continued our own in-house
development efforts. We have now carried out a total of 5
studies of hepatitis A vaccines in military volunteers.
A. Smith Kline
1
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 7 f:/Week-36/BX003205/HEPATITIS A - VACCINES/prevention of hepatitis a in soldiers:01029715472734
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003205
Unit = OTSG
Parent Organization = HSC
Folder Title = HEPATITIS A - VACCINES
Folder Seq # = 62
Subject = PREVENTION OF HEPATITIS A IN SOLDIERS
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997